Browse News
Filter News
Found 71 articles
-
After a sluggish start to the year, experts expect an uptick in IPO offerings moving into fall, although it’s unlikely 2023 will fully shrug off its slump.
-
Seed and Series A funding are set to drop this year as investors are looking for more advanced, less risky deals, according to an industry analysis from HSBC.
-
Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
5/19/2023
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy Annual Meeting.
-
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
5/17/2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.
-
Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
5/2/2023
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, announced it will present new data during the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting in Los Angeles (May 16-20).
-
Metagenomi Announces Participation in March 2023 Investor Conferences
3/6/2023
Metagenomi announced that it will participate in two upcoming investor conferences.
-
Ionis reports fourth quarter and full year 2022 financial results
2/22/2023
Ionis Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
At JPM Wednesday, Ionis CEO Brett Monia touted nine positive late- and mid-stage readouts from 2022 and set up the company's commercial prospects for 2023.
-
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
1/9/2023
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 48 programs in development, including 36 programs in clinical trials encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities.
-
Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.
-
BioSpace’s exclusive Hotbed Maps highlights nine different regions to watch across the U.S. The maps, made in vibrant color for BioSpace showcases a one-of-a-kind glance at some of 2023’s headline-making companies.
-
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
1/5/2023
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
Metagenomi to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Metagenomi today announced that Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.
-
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing
12/15/2022
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing.
-
The FDA has lifted its clinical hold on Beam Therapeutics’ BEAM-201 and cleared the way for an Investigational New Drug Application, the company announced Friday.
-
Mnemo Therapeutics Appoints Christine Foster, Ph.D. and Co-Founder Sebastian Amigorene, Ph.D. to Key Leadership Roles
11/30/2022
Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced the appointment of Christine Foster, Ph.D. to the role of Chief Business Officer.
-
Ionis Pharmaceuticals inked a collaboration deal with Metagenomi with the goal of adding DNA editing to its RNA-targeted technologies focused on up to four genetic targets.
-
Ionis partners with Metagenomi to add gene editing to its broad technology platform
11/14/2022
Ionis Pharmaceuticals, Inc. and Metagenomi announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.